Table 1.
Baseline Characteristics, Assessments And Treatments.
| Assessments | Intensive Management | Standard Care | |
|---|---|---|---|
| n = 168 | n = 167 | ||
| Demographic | Age (Years) | 56.4 (12.2) | 56.8 (12.0) |
| Disease Duration (Years) | 6.6 (7.0) | 5.2 (5.5) | |
| Female (%) | 140 (83%) | 130 (78%) | |
| Clinical Assessments | DAS28-ESR | 4.4 (0.5) | 4.3 (0.5) |
| DAS28-CRP | 4.5 (0.6) | 4.5 (0.6) | |
| CDAI | 19.7 (6.5) | 20.4 (6.8) | |
| SDAI | 20.6 (6.3) | 21.1 (6.6) | |
| Tender Joint counts (68 joints) | 12 (9) | 13 (9) | |
| Swollen joint counts (66 joints) | 6 (5) | 5 (4) | |
| Erythrocyte Sedimentation Rate (mm/hr) | 18 (14) | 15 (13) | |
| C-Reactive Protein (mg/L) | 8 (11) | 7 (8) | |
| Assessor Global Rating (mm) | 39 (18) | 41 (18) | |
| Patient Global Assessment (mm) | 43 (19) | 46 (21) | |
| Fatigue VAS (mm) | 59 (25) | 52 (25) | |
| Pain VAS (mm) | 40 (23) | 43 (23) | |
| Health Assessment Questionnaire | 1.2 (0.7) | 1.2 (0.7) | |
| EQ5D-5L | 0.71 (0.16) | 0.70 (0.19) | |
| Larsen Score | 11 (17) | 9 (11) | |
| Drug Treatments | Oral Methotrexate | 59 (35%) | 67 (40%) |
| Subcut Methotrexate | 22 (13%) | 19 (11%) | |
| Sulfasalazine | 30 (18%) | 19 (11%) | |
| Leflunomide | 12 (7%) | 11 (7%) | |
| Hydroxychloroquine | 29 (17%) | 37 (22%) | |
| Azathioprine | 1 (1%) | – | |
| Oral Methotrexate/Hydroxychloroquine | 7 (4%) | 8 (5%) | |
| Oral Methotrexate/Sulfasalazine | 2 (1%) | 1 (1%) | |
| Subcut Methotrexate/Hydroxychloroquine | 3 (2%) | 2 (1%) | |
| Subcut Methotrexate/Sulfasalazine | 2 (1%) | – | |
| Sulfasalazine/Hydroxychloroquine | 1 (1%) | 3 (2%) | |
Showing mean (standard deviation) or number (%). Subcut=subcutaneous; ESR= Erythrocyte Sedimentation Rate; CDAI= Clinical Disease Activity Index; SDAI= Simple Disease Activity Index; VAS= Visual Analogue Scale; DAS28-CRP= Disease Activity Score For 28 Joints Based On C-Reactive Protein; DAS28-ESR= Disease Activity Score for 28 Joints based on ESR; EQ5D-5L= EuroQol 5 Dimension (5 levels).